Literature DB >> 26759372

Prognostic Value of Treatment Setting in Patients With Cancer Having Pulmonary Embolism: Comparison With the Pulmonary Embolism Severity Index.

Shin Ahn1, Yoon-Seon Lee1, Won Young Kim1, Kyung Soo Lim1, Jae-Lyun Lee2.   

Abstract

BACKGROUND: Active cancer is a poor prognostic factor for survival after pulmonary embolism (PE). This retrospective cohort study was performed to investigate how accurately the pulmonary embolism severity index (PESI) predicts 30-day mortality in patients with active cancer. Whether the treatment setting (palliative vs curative) could predict mortality in these patients was also investigated.
METHODS: All consecutive patients with active cancer and PE who visited the emergency department of Asan Medical Center in January 2007 to June 2014 were identified. The covariates for predicting 30-day mortality were PESI classification, treatment setting (curative vs palliative), brain natriuretic peptide ≥ 150 ng/L, troponin I ≥ 0.10 ng/mL, right ventricular dysfunction, deep vein thrombosis, and anticoagulants used. Cox proportional hazards regression analysis was used to assess the association between treatment setting and 30-day mortality.
RESULTS: The PESI classification and 30-day mortality did not associate significantly. Area under the receiver-operating curve of the PESI was 0.565 (95% confidence interval [CI]: 0.453-0.677). Palliative treatment setting associated with an increased risk of 30-day mortality, regardless of the PESI classification (adjusted hazard ratio: 3.72, 95% CI: 1.49-9.26). Treatment setting predicted mortality 30 days, 3 months, and 6 months after PE presentation better than PESI.
CONCLUSION: The PESI did not accurately predict mortality in patients with active cancer. Treatment setting was the most important determinant of clinical outcome in these patients. When stratifying patients with active cancer and PE, palliative treatment setting should be considered as it is predictive of high mortality.

Entities:  

Keywords:  cancer; palliative treatment; prognosis; pulmonary embolism

Mesh:

Substances:

Year:  2016        PMID: 26759372     DOI: 10.1177/1076029615625826

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  2 in total

1.  Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism.

Authors:  Shin Ahn; Tim Cooksley; Srinivas Banala; Luke Buffardi; Terry W Rice
Journal:  Support Care Cancer       Date:  2018-05-04       Impact factor: 3.603

2.  Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism.

Authors:  Yuanyuan Sun; Xingguo Zhang; Hua Gao; Mingjie Liu; Qi Cao; Xinyang Kang; Yusheng Wang; Ling Zhu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.